Literature DB >> 27076587

Collapse phenomenon during Chartis collateral ventilation assessment.

Wolfgang Gesierich1, Konstantinos Samitas2, Frank Reichenberger3, Juergen Behr4.   

Abstract

Chartis is increasingly used for bronchoscopic assessment of collateral ventilation before endobronchial valve (EBV) treatment for severe emphysema. Its prognostic value is, however, limited by the airway collapse phenomenon. The frequency and clinical significance of the collapse phenomenon remain largely unknown.We performed a retrospective analysis of 92 patients undergoing Chartis evaluation under spontaneous breathing (n=55) or jet ventilation (n=37) from May 2010 to November 2013. Collateral ventilation status (positive/negative/collapse phenomenon/unclear) was reassessed and correlated with high-resolution computed tomography (HRCT) fissure analysis and clinical response.In the absence of the collapse phenomenon, the predictive value of Chartis measurements and HRCT fissural analysis was comparable. The collapse phenomenon was observed in 31.5% of all assessments, and was more frequent in lower lobes (44.9% versus 16.9% in upper lobes) and under jet ventilation (41.4% versus 22.1% under spontaneous breathing). 69.8% of lobes with the collapse phenomenon had complete fissures. Most patients with the collapse phenomenon in the target lobe and complete fissures treated with EBVs were responders (n=11/15). All valve-treated collapse phenomenon patients with fissure defects were nonresponders (n=3).In the absence of the collapse phenomenon Chartis measurement is reliable to predict response to valve treatment. In patients with the collapse phenomenon, treatment decisions should be based on HRCT detection of fissure integrity. Chartis assessment should be performed under spontaneous breathing.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2016        PMID: 27076587     DOI: 10.1183/13993003.01973-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice.

Authors:  Arschang Valipour
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 2.  Endobronchial Valves for Endoscopic Lung Volume Reduction: Best Practice Recommendations from Expert Panel on Endoscopic Lung Volume Reduction.

Authors:  Dirk-Jan Slebos; Pallav L Shah; Felix J F Herth; Arschang Valipour
Journal:  Respiration       Date:  2016-12-20       Impact factor: 3.580

3.  An Integrative Approach of the Fissure Completeness Score and Chartis Assessment in Endobronchial Valve Treatment for Emphysema.

Authors:  Karin Klooster; T David Koster; Christoph Ruwwe-Glösenkamp; Dorothea Theilig; Felix Doellinger; Jacopo Saccomanno; Huib A M Kerstjens; Dirk-Jan Slebos; Ralf-Harto Hübner
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-06-09

4.  Predictive value of Chartis measurement for lung function improvements in bronchoscopic lung volume reduction.

Authors:  Johannes Wienker; Rüdiger Karpf-Wissel; Faustina Funke; Christian Taube; Julia Wälscher; Jane Winantea; Sandra Maier; Khaled Mardanzai; Kaid Darwiche
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

5.  Clinical Utility of Quantitative CT Analysis for Fissure Completeness in Bronchoscopic Lung Volume Reduction: Comparison between CT and Chartis™.

Authors:  Sei Won Lee; So Youn Shin; Tai Sun Park; Yoon Young Choi; Jong Chun Park; Jina Park; Sang Young Oh; Namkug Kim; Se Hee Lee; Jae Seung Lee; Joon Beom Seo; Yeon Mok Oh; Sang Do Lee; Sang Min Lee
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

6.  An adjusted and time-saving method to measure collateral ventilation with Chartis.

Authors:  T David Koster; Karin Klooster; Hallie McNamara; Narinder S Shargill; Sri Radhakrishnan; Ryan Olivera; Dirk-Jan Slebos
Journal:  ERJ Open Res       Date:  2021-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.